Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

Phase 2

Terminated

• Conditions: Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer
• Interventions: Drug: Gemcitabine; Drug: nab-Paclitaxel

• Registration Number: NCT01851174
• Lead Sponsor: Western Regional Medical Center

Brief Summary

To determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

Detailed Description

This study will help determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly, opposed to a weekly, dosing schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

Study Timeline

• Study Start: 2013-02
• Study First Submitted: 2013-02-15
• Study First Submitted QC: 2013-05-09
• Study First Posted: 2013-05-10
• Primary Completion: 2015-01
• Study Completion: 2015-01
• Results First Submitted: 2017-09-27
• Results First Submitted QC: 2017-10-29
• Results First Posted: 2017-12-04
• Status Verified: 2018-01
• Last Update Submitted: 2018-01-11
• Last Update Posted: 2018-02-07

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Patients must have histologically-proven unresectable/metastatic pancreatic adenocarcinoma.

2. Patient has one or more radiographically measurable tumor.

3. Patients may have received prior adjuvant chemotherapy or radiation therapy (RT).

4. Age ≥ 18 years.

5. Patient must have read, understood, and provided written informed consent and HIPAA authorization after full explanation of the nature of the study.

6. ECOG performance status 0 - 2 and an expected survival of at least 3 months.

7. Acceptable hematological parameters within 2 weeks of commencing study therapy as follows:

   • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
   • Platelet count ≥ 100 x 10^9/L
   • Hemoglobin (Hgb) ≥ 9g/dl

8. Patients with adequate organ function as measured by:

   A. Cardiac: American Heart Association Class I: Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.

   B. Hepatic: Bilirubin ≤ 2.0 mg/ and ALT and AST ≤ 1.5x the upper limit of normal.

   C. Renal: Creatinine ≤ 1.5 mg/dl and no other chronic kidney disease.

9. Women must meet one of the following criteria:

   • Post-menopausal for at least one year
   • Surgically incapable of child-bearing
   • Utilizing a reliable form of contraception for the duration of study participation. Women of child-bearing potential must have a negative serum β-HCG within 7 days of study drug administration.

Exclusion Criteria

1. Previous use of nab-Paclitaxel for treatment of pancreatic cancer either as monotherapy or combination in neo-adjuvant, adjuvant, or the metastatic setting.
2. Previous use of any chemotherapy or radiation therapy for metastatic disease.
3. Patient has known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart).
4. Other significant active or chronic infection.
5. History of active other malignancy excluding basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.
6. Pregnant or nursing females.
7. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.
8. Major surgery, other than diagnostic surgery within 4 weeks of study entry.
9. Patient requires a legal authorized representative for consenting.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Gemcitabine and nab-Paclitaxel	nab-Paclitaxel	Gemcitabine (1,000 mg/m\^2) administered intravenously on days 1 and 15, every 28 days nab-Paclitaxel (125 mg/m\^2) administered intravenously on days 1 and 15, every 28 days
Gemcitabine and nab-Paclitaxel	Gemcitabine	Gemcitabine (1,000 mg/m\^2) administered intravenously on days 1 and 15, every 28 days nab-Paclitaxel (125 mg/m\^2) administered intravenously on days 1 and 15, every 28 days

Primary Outcome Measures

Name	Time	Method
Overall Survival Based on Toxicity Profile of Adverse Events.	One year	Determine the toxicity profile (decrease in hematological and non-hematological treatment-related AE's) with bi-weekly dosing of gemcitabine plus nab-Paclitaxel

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival Time	One year	Determine progression free survival time with this regimen

Trial Locations

Locations (1)

Western Regional Medical Center; 🇺🇸 Goodyear, Arizona, United States